Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA; Juvenile Dermatomyositis Research Group. Deakin CT, et al. Among authors: wedderburn lr. Arthritis Rheumatol. 2018 May;70(5):785-793. doi: 10.1002/art.40418. Epub 2018 Mar 25. Arthritis Rheumatol. 2018. PMID: 29342499 Free PMC article.
Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group. Deakin CT, et al. Among authors: wedderburn lr. Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753. Epub 2016 Oct 9. Arthritis Rheumatol. 2016. PMID: 27214289 Free PMC article.
Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition.
Shoop-Worrall SJW, Verstappen SMM, McDonagh JE, Baildam E, Chieng A, Davidson J, Foster H, Ioannou Y, McErlane F, Wedderburn LR, Thomson W, Hyrich KL. Shoop-Worrall SJW, et al. Among authors: wedderburn lr. Arthritis Rheumatol. 2018 Sep;70(9):1519-1529. doi: 10.1002/art.40519. Epub 2018 Jul 22. Arthritis Rheumatol. 2018. PMID: 29648683 Free PMC article.
Juvenile dermatomyositis: Latest advances.
Wu Q, Wedderburn LR, McCann LJ. Wu Q, et al. Among authors: wedderburn lr. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):535-557. doi: 10.1016/j.berh.2017.12.003. Epub 2018 Jan 10. Best Pract Res Clin Rheumatol. 2017. PMID: 29773272 Review.
Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models.
Deakin CT, Papadopoulou C, McCann LJ, Martin N, Al-Obaidi M, Compeyrot-Lacassagne S, Pilkington CA, Tansley SL, McHugh NJ, Wedderburn LR, De Stavola BL; Juvenile Dermatomyositis Research Group. Deakin CT, et al. Among authors: wedderburn lr. Rheumatology (Oxford). 2021 Apr 6;60(4):1891-1901. doi: 10.1093/rheumatology/keaa497. Rheumatology (Oxford). 2021. PMID: 33146389 Free PMC article.
220 results